Osmotica Pharmaceuticals to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
BRIDGEWATER, N.J., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference as follows:
| Date: | Wednesday, December 12, 2018 |
| Time: | 2:00 p.m. Eastern Standard Time |
| Location: | Mandarin Oriental New York, New York |
| Webcast: | https://cc.talkpoint.com/bmoc001/121218a_as/?entity=35_CHO3XLW |
The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.osmotica.com, under the “Investor & News” section.
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. Our diversified product portfolio in the specialty neurology and women's health therapeutic areas, together with our non-promoted complex formulations of generic drugs, form the foundation of our unwavering commitment to improve patients' lives.
Osmotica has a late‑stage development pipeline highlighted by two NDA candidates in Phase III clinical trials: arbaclofen extended‑release tablets for muscle spasticity in multiple sclerosis patients and RVL‑1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for the treatment of blepharoptosis, or droopy eyelid.
Osmotica has operations in the United States, Argentina, and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
